Benzinga | Oct 21, 2021 12:11PM EDT

Zynerba Pharmaceuticals Announces Presentations At Two Upcoming Scientific Conferences In October

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced oral and poster presentations at the Society for Developmental & Behavioral Pediatrics Annual Meeting, being held virtually October 21-25, 2021, and the 68th American Academy of Child & Adolescent Psychiatry Annual Meeting, being held virtually October 18-30, 2021.

Presentation Details

Society for Developmental & Behavioral Pediatrics (SDBP) Annual Meeting

A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel inTitle Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]Presentation OralTypeSession Platform 2: NDD Phenotypes and TreatmentDate Saturday, October 23, 2021Time 4:00 ? 5:30 p.m. ET



Longer Term Tolerability and Efficacy of ZYN002 CannabidiolTitle Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder (ASD): An Open-Label Phase 2 Study (BRIGHT [ZYN2-CL-030])Presentation PosterTypeSession Poster Session 2: Neurodevelopmental Disabilities, COVID-19Date Monday, October 25, 2021Time 1:45 ? 2:45 p.m.



68th American Academy of Child & Adolescent Psychiatry (AACAP) Annual Meeting

RECONNECT (ZYN2-CL-033): Design of a Phase 3 Trial of ZYN002Title Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome Based Upon Learnings from CONNECT-FX (ZYN2-CL-016)Presentation OralTypeSession Research Pipeline: New Findings on Diagnostic and TherapeuticsDate Wednesday, October 27, 2021Time 3:15 p.m. ? 5:30 p.m. ET



Longer-Term Tolerability and Efficacy of ZYN002 CannabidiolTitle Transdermal Gel in Children and Adolescents With Autism Spectrum Disorder: An Open-Label Phase 2 Study (BRIGHT [ZYN2-CL-030])Presentation OralTypeSession Research Pipeline: New Findings on Diagnostic and TherapeuticsDate Wednesday, October 27, 2021Time 3:15 p.m. ? 5:30 p.m. ET

Copies of the presentations and posters will be available on the Zynerba corporate website following each presentation at http://zynerba.com/publications/.